$0.48
-0.02 (-3.98%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BEAT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 2 observational
Held by 1 tracked-famous manager (TWO SIGMA INVESTMENTS, LP) · FINRA short interest 4.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| HeartBeam ECG RegistryNCT07501299observationalCreation of a de-identified ECG dataset for future research and regulatory use | — | Recruiting | Diagnostic test: Electrocardiogram (ECG) | Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia, Arrhythmia | 600 | Dec 2028 | ≤ 865 d | 2026-07-20 |
| ALIGN-ACS Pilot StudyNCT07715474observationalSensitivity and specificity of the HeartBeam ECG for detection of ACS | — | Active, not recruiting | Diagnostic test: ECG | Acute Coronary Syndromes | 120 | 2026-06-30actual | — | 2026-07-20 |
| AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia DetectionNCT06123130Clinical equivalence of ECG intervals compared between AIMIGo Synthesized 12L and reference standard 12LOpen-label · Diagnostic | Not applicable | Completed | Device: Vectorcardiography (VECG) | Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia | 198 | 2024-06-20actual | — | 2024-07-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19